Testing pembrolizumab with chemo before breast cancer surgery
Part of Cancer, Skin clinical trials.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy before surgery improves immune and clinical responses in people with early-stage triple-negative breast cancer. You may benefit by getting a potentially more effective treatment plan, while the study team closely monitors your response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed, early breast cancer (stage II or III) that has not spread to distant organs
- Your tumor is triple-negative: estrogen receptor (ER) 10% or less, progesterone receptor (PR) 10% or less, and HER2 is negative
- You have never had chemo, hormone (endocrine) therapy, or immunotherapy before starting this study
- You can attend all scheduled visits and follow the treatment and lab testing plan
- You agree by signing informed consent after learning the risks and study procedures
- You can use birth control during the study if you could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving more of the immunotherapy drug pembrolizumab (Keytruda) after surgery helps people with early-stage triple-negative breast cancer that did not completely disappear with the initial chemotherapy plus immunotherapy. This is for patients who still have some cancer left after surgery, to reduce the chance of it coming back.
This trial tests a new approach for breast cancer that combines a short course of focused radiation (SBRT) with an injection of the immunotherapy drug pembrolizumab directly into the tumor, followed by standard chemotherapy before surgery. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
This trial tests two different sequences of chemotherapy combined with pembrolizumab (an immunotherapy drug) given before surgery for high-risk triple-negative breast cancer. The goal is to see which sequence works better at shrinking or eliminating the tumor.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This study looks at how well a treatment combining pembrolizumab (an immunotherapy drug) with chemotherapy works before surgery for triple-negative breast cancer. It aims to understand the benefits and side effects in real-world patients.
Hear when a new Breast Cancer Triple Negative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.